No Cover Image

Journal article 331 views 52 downloads

Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study

Mads Damkjaer Orcid Logo, Stine Kjaer Urhoj Orcid Logo, Joachim Tan, Gillian Briggs Orcid Logo, Maria Loane, Joanne Emma Given Orcid Logo, Laia Barrachina-Bonet, Clara Cavero-Carbonell Orcid Logo, Alessio Coi Orcid Logo, Amanda J Neville, Anna Heino, Sonja Kiuru-Kuhlefelt, Sue Jordan Orcid Logo, Ieuan Scanlon, Anna Pierini, Aurora Puccini, Ester Garne Orcid Logo, Joan K Morris Orcid Logo

BMJ Open, Volume: 12, Issue: 4, Start page: e057400

Swansea University Authors: Sue Jordan Orcid Logo, Ieuan Scanlon

  • 60078.pdf

    PDF | Version of Record

    © Author(s) (or their employer(s)) 2022. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license

    Download (607.03KB)

Check full text

DOI (Published version): 10.1136/bmjopen-2021-057400

Abstract

Objectives Advances in surgical management strategies have substantially reduced fatality from congenital heart defects (CHD). Decreased infant mortality might be expected, consequentially to result in greater morbidity in older children due to complications later in childhood and adolescence. This...

Full description

Published in: BMJ Open
ISSN: 2044-6055 2044-6055
Published: BMJ 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60078
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-06-23T09:42:41Z
last_indexed 2022-06-24T03:19:05Z
id cronfa60078
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-06-23T10:44:29.4469809</datestamp><bib-version>v2</bib-version><id>60078</id><entry>2022-05-24</entry><title>Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study</title><swanseaauthors><author><sid>24ce9db29b4bde1af4e83b388aae0ea1</sid><ORCID>0000-0002-5691-2987</ORCID><firstname>Sue</firstname><surname>Jordan</surname><name>Sue Jordan</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>9fcb224c6bd804a4d41a2a8570a71185</sid><firstname>Ieuan</firstname><surname>Scanlon</surname><name>Ieuan Scanlon</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-05-24</date><deptcode>HNU</deptcode><abstract>Objectives Advances in surgical management strategies have substantially reduced fatality from congenital heart defects (CHD). Decreased infant mortality might be expected, consequentially to result in greater morbidity in older children due to complications later in childhood and adolescence. This study aims to evaluate the use of cardiovascular medication (CVM) as an indicator of disease burden in children born with CHD in the first 10 years of life.Design Population-based cohort study.Setting Six population-based registries from the European Surveillance of Congenital Anomalies (EUROCAT) network participated. Data from live born children with major congenital anomalies (CA) born from 2000 to 2014 were linked to prescription databases. Four groups of children were analysed: CA, CHD, severe CHD (sCHD) and ventricular septal defect (VSD) without sCHD. Live born children without CA were included as reference group.Participants We obtained data on 61&#x2009;038 children born with a CA, including 19&#x2009;678 with CHD, 3392 with sCHD, 12&#x2009;728 children with VSD without sCHD, and 1&#x2009;725&#x2009;496 reference children.Results Children born with sCHD were the most likely to receive a CVM prescription (42.9%, 95%&#x2009;CI, 26.3 to 58.5) in the first year of life compared with 13.3% (6.7 to 22.0) of children with any CHD, 5.9% (3.7 to 8.7) of children with any CA and 0.1% (0.0 to 0.1) of reference children. Medication was less likely to be prescribed after the first year of life for sCHD; 18.8% (14.8 to 23.1) for children 1&#x2013;4 years and 15.8% (12.0 to 20.1) 5&#x2013;9 years. Children with sCHD were most likely to receive a diuretic (36.4%, 18.6 to 54.5), an antihypertensive (6.9%, 3.7 to 11.3) or a beta-blocker (5.5%, 2.9 to9.2).Conclusion Almost half of all children with sCHD were prescribed CVM in their first year of life. For all four groups of children with anomalies, the proportion of children with a CVM prescription decreased with age.</abstract><type>Journal Article</type><journal>BMJ Open</journal><volume>12</volume><journalNumber>4</journalNumber><paginationStart>e057400</paginationStart><paginationEnd/><publisher>BMJ</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2044-6055</issnPrint><issnElectronic>2044-6055</issnElectronic><keywords/><publishedDay>21</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-04-21</publishedDate><doi>10.1136/bmjopen-2021-057400</doi><url/><notes/><college>COLLEGE NANME</college><department>Nursing</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HNU</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This study has received funding from the European Union&#x2019;s Horizon 2020 research and innovation programme under grant agreement No. 733001.</funders><lastEdited>2022-06-23T10:44:29.4469809</lastEdited><Created>2022-05-24T20:27:56.3400694</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">School of Health and Social Care - Nursing</level></path><authors><author><firstname>Mads</firstname><surname>Damkjaer</surname><orcid>0000-0001-7410-8573</orcid><order>1</order></author><author><firstname>Stine Kjaer</firstname><surname>Urhoj</surname><orcid>0000-0002-2069-9723</orcid><order>2</order></author><author><firstname>Joachim</firstname><surname>Tan</surname><order>3</order></author><author><firstname>Gillian</firstname><surname>Briggs</surname><orcid>0000-0001-7535-8398</orcid><order>4</order></author><author><firstname>Maria</firstname><surname>Loane</surname><order>5</order></author><author><firstname>Joanne Emma</firstname><surname>Given</surname><orcid>0000-0003-4921-1944</orcid><order>6</order></author><author><firstname>Laia</firstname><surname>Barrachina-Bonet</surname><order>7</order></author><author><firstname>Clara</firstname><surname>Cavero-Carbonell</surname><orcid>0000-0002-4858-6456</orcid><order>8</order></author><author><firstname>Alessio</firstname><surname>Coi</surname><orcid>0000-0002-9816-3144</orcid><order>9</order></author><author><firstname>Amanda J</firstname><surname>Neville</surname><order>10</order></author><author><firstname>Anna</firstname><surname>Heino</surname><order>11</order></author><author><firstname>Sonja</firstname><surname>Kiuru-Kuhlefelt</surname><order>12</order></author><author><firstname>Sue</firstname><surname>Jordan</surname><orcid>0000-0002-5691-2987</orcid><order>13</order></author><author><firstname>Ieuan</firstname><surname>Scanlon</surname><order>14</order></author><author><firstname>Anna</firstname><surname>Pierini</surname><order>15</order></author><author><firstname>Aurora</firstname><surname>Puccini</surname><order>16</order></author><author><firstname>Ester</firstname><surname>Garne</surname><orcid>0000-0003-0430-2594</orcid><order>17</order></author><author><firstname>Joan K</firstname><surname>Morris</surname><orcid>0000-0002-7164-612x</orcid><order>18</order></author></authors><documents><document><filename>60078__24376__d92d7085709f4478b375dd01a567c604.pdf</filename><originalFilename>60078.pdf</originalFilename><uploaded>2022-06-23T10:43:01.9276242</uploaded><type>Output</type><contentLength>621596</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; Author(s) (or their employer(s)) 2022. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-06-23T10:44:29.4469809 v2 60078 2022-05-24 Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study 24ce9db29b4bde1af4e83b388aae0ea1 0000-0002-5691-2987 Sue Jordan Sue Jordan true false 9fcb224c6bd804a4d41a2a8570a71185 Ieuan Scanlon Ieuan Scanlon true false 2022-05-24 HNU Objectives Advances in surgical management strategies have substantially reduced fatality from congenital heart defects (CHD). Decreased infant mortality might be expected, consequentially to result in greater morbidity in older children due to complications later in childhood and adolescence. This study aims to evaluate the use of cardiovascular medication (CVM) as an indicator of disease burden in children born with CHD in the first 10 years of life.Design Population-based cohort study.Setting Six population-based registries from the European Surveillance of Congenital Anomalies (EUROCAT) network participated. Data from live born children with major congenital anomalies (CA) born from 2000 to 2014 were linked to prescription databases. Four groups of children were analysed: CA, CHD, severe CHD (sCHD) and ventricular septal defect (VSD) without sCHD. Live born children without CA were included as reference group.Participants We obtained data on 61 038 children born with a CA, including 19 678 with CHD, 3392 with sCHD, 12 728 children with VSD without sCHD, and 1 725 496 reference children.Results Children born with sCHD were the most likely to receive a CVM prescription (42.9%, 95% CI, 26.3 to 58.5) in the first year of life compared with 13.3% (6.7 to 22.0) of children with any CHD, 5.9% (3.7 to 8.7) of children with any CA and 0.1% (0.0 to 0.1) of reference children. Medication was less likely to be prescribed after the first year of life for sCHD; 18.8% (14.8 to 23.1) for children 1–4 years and 15.8% (12.0 to 20.1) 5–9 years. Children with sCHD were most likely to receive a diuretic (36.4%, 18.6 to 54.5), an antihypertensive (6.9%, 3.7 to 11.3) or a beta-blocker (5.5%, 2.9 to9.2).Conclusion Almost half of all children with sCHD were prescribed CVM in their first year of life. For all four groups of children with anomalies, the proportion of children with a CVM prescription decreased with age. Journal Article BMJ Open 12 4 e057400 BMJ 2044-6055 2044-6055 21 4 2022 2022-04-21 10.1136/bmjopen-2021-057400 COLLEGE NANME Nursing COLLEGE CODE HNU Swansea University This study has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 733001. 2022-06-23T10:44:29.4469809 2022-05-24T20:27:56.3400694 Faculty of Medicine, Health and Life Sciences School of Health and Social Care - Nursing Mads Damkjaer 0000-0001-7410-8573 1 Stine Kjaer Urhoj 0000-0002-2069-9723 2 Joachim Tan 3 Gillian Briggs 0000-0001-7535-8398 4 Maria Loane 5 Joanne Emma Given 0000-0003-4921-1944 6 Laia Barrachina-Bonet 7 Clara Cavero-Carbonell 0000-0002-4858-6456 8 Alessio Coi 0000-0002-9816-3144 9 Amanda J Neville 10 Anna Heino 11 Sonja Kiuru-Kuhlefelt 12 Sue Jordan 0000-0002-5691-2987 13 Ieuan Scanlon 14 Anna Pierini 15 Aurora Puccini 16 Ester Garne 0000-0003-0430-2594 17 Joan K Morris 0000-0002-7164-612x 18 60078__24376__d92d7085709f4478b375dd01a567c604.pdf 60078.pdf 2022-06-23T10:43:01.9276242 Output 621596 application/pdf Version of Record true © Author(s) (or their employer(s)) 2022. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license true eng http://creativecommons.org/licenses/by-nc/4.0/
title Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study
spellingShingle Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study
Sue Jordan
Ieuan Scanlon
title_short Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study
title_full Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study
title_fullStr Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study
title_full_unstemmed Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study
title_sort Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study
author_id_str_mv 24ce9db29b4bde1af4e83b388aae0ea1
9fcb224c6bd804a4d41a2a8570a71185
author_id_fullname_str_mv 24ce9db29b4bde1af4e83b388aae0ea1_***_Sue Jordan
9fcb224c6bd804a4d41a2a8570a71185_***_Ieuan Scanlon
author Sue Jordan
Ieuan Scanlon
author2 Mads Damkjaer
Stine Kjaer Urhoj
Joachim Tan
Gillian Briggs
Maria Loane
Joanne Emma Given
Laia Barrachina-Bonet
Clara Cavero-Carbonell
Alessio Coi
Amanda J Neville
Anna Heino
Sonja Kiuru-Kuhlefelt
Sue Jordan
Ieuan Scanlon
Anna Pierini
Aurora Puccini
Ester Garne
Joan K Morris
format Journal article
container_title BMJ Open
container_volume 12
container_issue 4
container_start_page e057400
publishDate 2022
institution Swansea University
issn 2044-6055
2044-6055
doi_str_mv 10.1136/bmjopen-2021-057400
publisher BMJ
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str School of Health and Social Care - Nursing{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}School of Health and Social Care - Nursing
document_store_str 1
active_str 0
description Objectives Advances in surgical management strategies have substantially reduced fatality from congenital heart defects (CHD). Decreased infant mortality might be expected, consequentially to result in greater morbidity in older children due to complications later in childhood and adolescence. This study aims to evaluate the use of cardiovascular medication (CVM) as an indicator of disease burden in children born with CHD in the first 10 years of life.Design Population-based cohort study.Setting Six population-based registries from the European Surveillance of Congenital Anomalies (EUROCAT) network participated. Data from live born children with major congenital anomalies (CA) born from 2000 to 2014 were linked to prescription databases. Four groups of children were analysed: CA, CHD, severe CHD (sCHD) and ventricular septal defect (VSD) without sCHD. Live born children without CA were included as reference group.Participants We obtained data on 61 038 children born with a CA, including 19 678 with CHD, 3392 with sCHD, 12 728 children with VSD without sCHD, and 1 725 496 reference children.Results Children born with sCHD were the most likely to receive a CVM prescription (42.9%, 95% CI, 26.3 to 58.5) in the first year of life compared with 13.3% (6.7 to 22.0) of children with any CHD, 5.9% (3.7 to 8.7) of children with any CA and 0.1% (0.0 to 0.1) of reference children. Medication was less likely to be prescribed after the first year of life for sCHD; 18.8% (14.8 to 23.1) for children 1–4 years and 15.8% (12.0 to 20.1) 5–9 years. Children with sCHD were most likely to receive a diuretic (36.4%, 18.6 to 54.5), an antihypertensive (6.9%, 3.7 to 11.3) or a beta-blocker (5.5%, 2.9 to9.2).Conclusion Almost half of all children with sCHD were prescribed CVM in their first year of life. For all four groups of children with anomalies, the proportion of children with a CVM prescription decreased with age.
published_date 2022-04-21T04:17:53Z
_version_ 1763754191952543744
score 11.016235

Similar Items